MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

CCBs

  • Home
  • CCBs
ARBs versus Dihydropyridine CCBs : Which Protects the Heart and Which Safeguards the Kidneys?
Posted inCardiology Nephrology news Specialties

ARBs versus Dihydropyridine CCBs : Which Protects the Heart and Which Safeguards the Kidneys?

Posted by By MedXY 08/10/2025
Comparative review of angiotensin receptor blockers (ARBs, “沙坦”) and dihydropyridine calcium‑channel blockers (DHP‑CCBs, “地平类”) focused on organ protection—kidney, heart and brain—and practical selection based on comorbidity and evidence.
Read More
  • Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion
  • Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4
  • Natural History and Treatment Outcomes in Hemorrhagic Moyamoya Disease: Insights from a Large Chinese Cohort
  • Unraveling Bibrachial Amyotrophy in Spontaneous Spinal CSF Leaks: Clinical Insights and Surgical Outcomes
  • Circulating Metabolites as Emerging Biomarkers for Stroke Risk Prediction: Insights from the BiomarCaRE Project
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top